Asset Details
Do you wish to reserve the book?
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose
Do you wish to request the book?
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose
2017
Overview
It remains unclear why the dose of xanthine oxidase inhibitors (XOI) allopurinol or febuxostat varies among patients though they reach similar serum uric acid (SUA) goal. We pursued genomic sequencing of XOI metabolism and clearance genes to identify single-nucleotide polymorphisms (SNPs) relate to differences in XOI dose. Subjects with a diagnosis of Gout based on the 1977 American College of Rheumatology Classification Criteria for the disorder, who were on stable doses of a XOI, and who were at their goal SUA level, were enrolled. The primary outcome was relationship between SNPs in any of these genes to XOI dose. The secondary outcome was relationship between SNPs and change in pre- and post-treatment SUA. We enrolled 100 subjects. The average patient age was 68.6 ± 10.6 years old. Over 80% were men and 77% were Caucasian. One SNP was associated with a higher XOI dose: rs75995567 (
p
= 0.031). Two SNPs were associated with 300 mg daily of allopurinol: rs11678615 (
p
= 0.022) and rs3731722 on
Aldehyde Oxidase
(
AO
) (His1297Arg) (
p
= 0.001). Two SNPs were associated with a lower dose of allopurinol: rs1884725 (
p
= 0.033) and rs34650714 (
p
= 0.006). For the secondary outcome, rs13415401 was the only SNP related to a smaller mean SUA change. Ten SNPs were identified with a larger change in SUA. Though multiple SNPs were identified in the primary and secondary outcomes of this study, rs3731722 is known to alter catalytic function for some aldehyde oxidase substrates.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
